

**INTERNATIONAL UNION OF
PURE AND APPLIED CHEMISTRY
AND
INTERNATIONAL UNION OF BIOCHEMISTRY**

**DEFINITIVE RULES FOR NAMING
SYNTHETIC MODIFICATIONS
OF NATURAL PEPTIDES**

*Issued by the
IUPAC–IUB Commission on Biochemical Nomenclature
1971*

**LONDON
BUTTERWORTHS**

647

IUPAC-IUB COMMISSION
ON BIOCHEMICAL NOMENCLATURE†

**DEFINITIVE RULES FOR NAMING SYNTHETIC
MODIFICATIONS OF NATURAL PEPTIDES**

During the last few years, chemists have made many compounds that are variants of naturally occurring peptides (or proteins) having trivial names. Therefore, the need has arisen for 'semitrivial' names to designate these variants without the necessity of designating every residue in the chain.

After discussion with active workers in the field, tentative rules were proposed by the IUPAC-IUB Commission on Biochemical Nomenclature (CBN) and published in *IUPAC Information Bulletin* No. 27 (1966)‡. They are based on the names used by du Vigneaud and his collaborators [cf. Bodanszky and du Vigneaud, *J. Amer. Chem. Soc.* **81**, 1258 (1959); Popenoe, Lawler and du Vigneaud, *J. Amer. Chem. Soc.* **74**, 3713 (1952)] and the symbols introduced by Schwyzer *et al.* [cf. Rittel, Iselin, Kappeler, Riniker and Schwyzer, *Angew. Chem.* **69**, 179 (1957); Riniker and Schwyzer, *Helv. Chim. Acta*, **44**, 685 (1961); see also *J. Biol. Chem.* **247**, 977 (1972).

The definitive rules are based on the comments that were received. They are *not* suitable for application to 'abnormal' links in a peptide sequence; e.g. to disulfide links or γ -peptide links. They are *only* suitable for modifications involving normal α -peptide links.

RULES

1. Replacement

In a polypeptide of trivial name X, if the qth amino acid residue (starting from the N-terminal end of the chain) is *replaced* by the amino acid residue Abc, the semitrivial name of the modified polypeptide is [q-amino acid]X and the abbreviated form, chiefly for use in tables, is [Abc^q]X.

Examples

[8-Citrulline]vasopressin, [Cit⁸]vasopressin [Bodanszky and Birkhimer, *J. Amer. Chem. Soc.* **84**, 4963 (1962)]. [5-Isoleucine, 7-alanine]hypertensin II, [Ile⁵, Ala⁷]hypertensin II [Seu, Smeby and Bumpus, *J. Amer. Chem. Soc.* **84**, 3883 (1962)].

† Those who have served on the Commission for varying periods during 1967-71 are the following. Present Members are shown by an asterisk *. O. Hoffmann-Ostenhof* (Chairman), W. E. Cohn* (Secretary), A. E. Braunstein*, J. S. Fruton, B. L. Horecker*, P. Karlson*, B. Keil*, W. Klyne*, C. Liébecq*, B. C. Malmström, R. Schwyzer, E. C. Slater, E. C. Webb*, W. J. Whelan*. Comments on and suggestions for future revisions of these rules should be sent to: Prof. O. Hoffmann-Ostenhof, Lehrkanzel für Biochemie der Universität Wien, Währinger Strasse 38, A-1090 Wien, Austria.

‡ Also published in *J. Biol. Chem.* **242**, 555 (1967) and in other journals.

BIOCHEMICAL NOMENCLATURE

Comments

(a) In the full name, the replacement amino acid is designated by its *own full name*, *not* the name of its radical (cf. 4 below). This name, and the position of replacement, are given in square brackets [], as for isotopic replacement.

(b) In the abbreviated form, the amino-acid residues are designated by the standard three-letter symbols [*J. Biol. Chem.* **241**, 527 (1966); *Biochim. Biophys. Acta*, **121**, 1 (1966); also **247**, 977 (1972)], the first letter *only* being a capital, in square brackets [].

(c) In the abbreviated form, the *position* of substitution is indicated in a special fashion, i.e. by a superior numeral^a, to indicate that it is a *residue*, not an individual atom, that is being replaced and also for the reason indicated in comment d.

(d) The nature of the residue replaced is *not* designated in either the full or the abbreviated name. This is contrary to a general principle of organic nomenclature requiring that an atom (or group) that is replaced should (unless it is hydrogen) be clearly designated, as in 2-amino-2-deoxy-D-glucose. It has been decided *not* to insist on the designation of the residue replaced in these semitrivial names in order to keep the names as short as possible, and because the form of nomenclature in Rule 1 clearly differs from ordinary substitution nomenclature.

(e) An analogy may be drawn with the form used for isotopic replacement, where the isotope symbol is indicated in square brackets before the name.

(f) The replacement of an amino-acid residue by its enantiomer may be shown logically by the application of this rule as follows: the replacement in X of L-alanine at position 7 by D-alanine results in [7-D-alanine]X with the abbreviation [D-Ala⁷]X. An example may be found in R. A. Boissonnas, St. Guttmann and J. Pless [*Experientia*, **22**, 526 (1966)], dealing with the D-Ser¹ ... derivative of β -corticotropin; the natural compound has L-serine in position 1. Another example is the [α -D-Asp¹]hypertensin II of Riniker and Schwyzler [*Helv. Chim. Acta*, **47**, 2357 (1964)].

2 Extension

The compounds obtained by the extension of polypeptide X at either (a) the N-terminal end or (b) the C-terminal end are designated by the kinds of names and abbreviations shown below; these are in accordance with the general principles of polypeptide nomenclature [*J. Biol. Chem.* **247**, 977 (1972)].

Examples

(a) Extension at N-terminal end:

Aminoacyl-X Abc-X

e.g. Valyl-X Val-X

or Valylglycyl-X Val-Gly-X (for extension by two residues)

(b) Extension at C-terminal end:

X-yl-amino acid X-yl-Abc

e.g. X-yl-leucine X-yl-Leu

(where X-yl is the trivial name of polypeptide X with the ending -yl).

NAMING MODIFICATIONS OF NATURAL PEPTIDES

Comment

This rule is not applicable to the extension at the C-terminal of natural peptides having a terminal α -carboxamido group, as in the case of oxytocin or α -melanophore-stimulating hormone (α -MSH). It has been suggested that new names be given to the peptides having a free terminal α -carboxyl group (e.g. oxytocinoic acid) and that extension at the C-terminal end be denoted as in the example given above (e.g. oxytocinoyl-Abc).

3. Insertion

The compound obtained by the *insertion* of an additional amino acid residue Abc in the position between the qth and (q + 1)th residues of a polypeptide X is named qa-endo-amino acid-X (abbreviated form, endo-Abc^{qa}-X).

Example

4a-endo-tyrosine-hypertensin II; endo-Tyr^{4a}-hypertensin II.

Comments

(a) This form has analogies in other fields where endo implies the insertion of something into a structure (e.g. endo-methylene). The prefix or index qa is based on analogies with the steroids where the atoms inserted in a ring atom no. q are designated qa, qb, etc.

(b) The prefix homo is *not* suitable for designating the insertion of a whole residue, since it is commonly used to modify the names of *individual* amino acids, e.g. homoserine.

(c) Multiple insertions, and insertion of two or more residues together in the same place in the chain, are shown by a logical extension of this rule. For example, the insertion into the polypeptide X of threonine between residues 4 and 5, and of valine and glycine (*in that order*) between residues 6 and 7, is shown by the name 'endo-4a-threonine,6a-valine,6b-glycine-X' and the abbreviation 'endo-Thr^{4a}, (Val^{6a}-Gly^{6b})-X.'

4. Removal

The compound obtained by the formal *removal* of an amino acid residue from a polypeptide X in position q is designated by the name des-q-amino acid-X, abbreviated des-Abc^q-X.

Example

des-7-proline-oxytocin; des-Pro⁷-oxytocin [Jacquenoud and Boissonnas. *Helv. Chim. Acta*, 45, 1462 (1962)].

Comment

(a) Removal of a whole residue is indicated as is the removal of a ring in steroids, e.g. des-A-androstane.

(b) 'de' is *not* suitable as a prefix because it is easily confused, in speaking, with D (for configuration).

5. Substitution forming a sidechain


The compound formed by the substitution of an additional amino acid

residue as a sidechain into a polypeptide X is named by applying the ordinary rules of nomenclature to the trivial name.

(a) If the substitution is on a sidechain *amino* group of polypeptide X, the name of the additional amino *residue* is written (with the termination 'yl') and prefixed by symbols indicating the position of substitution (residue number and atom).

Example

An imaginary compound (A)




in which a valyl group is substituted at the ϵ -amino group of lysine at position 2 of the chain of a peptide X is named $N^{\epsilon 2}$ -valyl-X (abbreviated $N^{\epsilon 2}$ -Val-X).

(b) If the substitution is on a sidechain *carboxyl* group of polypeptide X, the additional amino acid having a free α -carboxyl group, the substituted derivative is named by specifying the position of substitution (residue number, and atom) and is given the designation 'X-amino acid'.

Example

An imaginary compound (B)



in which a valine residue is substituted into the δ -carboxyl group of glutamic acid in position 3 of the chain of a peptide X would be named $C^{\delta 3}$ -X-yl-valine (abbreviated $C^{\delta 3}$ -X-yl-Val).

Comment

Note the importance of clear distinction from *replacement* as indicated in Rule 1.

6. Partial sequences (fragments)

Polypeptide sequences that form fragments of a longer sequence that already has a trivial name may be designated as follows. The *trivial name* is followed by numbers giving the positions of the first and last amino acids, and then the usual *Greek* designation giving the number of amino acid units in the fragment; thus

Trivial name(-X-Y-) peptide.

Example: from α -MSH

we may have

and

The last example illustrates the nomenclature for a composition sequence of two fragments, and also for an amide-terminal group.

The systematic application of these principles to the name of an imaginary pentapeptide 'Iupaciubin'* may illustrate the symbolism.

Rule	Operation	Short name	Structure
	(Fundamental name)	Iupaciubin	$\begin{array}{ccccc} 1 & 2 & 3 & 4 & 5 \\ \text{Ala-Lys-Glu-Tyr-Leu} \end{array}$
1.	Replacement	[Phe ⁴]iupaciubin [†]	$\begin{array}{ccccc} & & & 4 & \\ \text{Ala-Lys-Glu-Phe-Leu} \end{array}$
2a.	Extension (N terminal)	Arginyl-iupaciubin, Arg-iupaciubin	$\begin{array}{ccccc} & 1 & & & 5 \\ \text{Arg-Ala-Lys-Glu-Tyr-Leu} \end{array}$
2b.	Extension (C terminal)	Iupaciubyl-methionine, iupaciubyl-Met	$\begin{array}{ccccc} & 1 & & & 5 \\ \text{Ala-Lys-Glu-Tyr-Leu-Met} \end{array}$
3.	Insertion	Endo-Thr ^{2a} -iupaciubin	$\begin{array}{ccccc} & 2 & 2a & 3 & \\ \text{Ala-Lys-Thr-Glu-Tyr-Leu} \end{array}$
4.	Removal	Des-Glu ³ -iupaciubin	$\begin{array}{ccccc} & 2 & 4 & & \\ \text{Ala-Lys-Tyr-Leu} \end{array}$
5a.	Sidechain substitution on amino group	N ^{ε2} -Val-iupaciubin	$\begin{array}{ccccc} & \text{Val} & & & \\ & & & & \\ & \epsilon & & & \\ \text{Ala-Lys-Glu-Tyr-Leu} \end{array}$
5b.	Sidechain substitution on carboxyl group	C ^{δ3} -Iupaciubyl-valine	$\begin{array}{ccccc} & & \text{Val} & & \\ & & & & \\ & & \delta & & \\ \text{Ala-Lys-Glu-Tyr-Leu} \end{array}$
6.	Partial sequence	Iupaciubin-(2-4)-tripeptide	$\begin{array}{ccccc} & 2 & 3 & 4 & \\ \text{Lys-Glu-Tyr} \end{array}$

* To symbolize the harmonious cooperation of IUPAC and IUB.

† Note that only for *replacement* are square brackets required.